Soligenix to work with University of Hawaii, Hawaii Biotech on Ebola; Medigene's dendritic cell vaccines receive patent extention;

> Princeton, NJ-based Soligenix inked a collaboration agreement with the University of Hawaii at Manoa and Hawaii Biotech to work on a heat stable Ebola vaccine. Release

> The U.S. Patent Office extended Medigene's patent for dendritic cell vaccines to 2031. Brief

> Noting a potential for a hypertension vaccine, researchers found in a study of rats that three needless injections delivered lowered blood pressure for up to six months. More

> Research published in mBio suggests a protein called Niemann-Pick C1 to be the "Achilles' heel" of Ebola. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.